Kasujee相关文献与解析，生知库 | 链接生命科学的每一步

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol

一项欧洲多中心前瞻性观察性IV期临床研究，旨在评估lebrikizumab对中重度特应性皮炎患者健康相关福祉和皮肤表现控制的影响（ADTrust）：研究方案

doi:10.1136/bmjopen-2025-102155

Augustin, Matthias; Bewley, Anthony; Brüggen, Marie-Charlotte; de Bruin-Weller, Marjolein S; Ezzedine, Khaled; Ferrucci, Silvia M; Gkalpakiotis, Spyridon; Herranz, Pedro; Johansson, Emma K; Kampe, Tomáš; Lapeere, Hilde; Legat, Franz J; Rehbinder, Eva Maria; Szepietowski, Jacek C; Torres, Tiago; Vestergaard, Christian; Werfel, Thomas; Domenech, Arnau; Massana, Eric; Koscielny, Volker; Narayanan, Siva; Kasujee, Ismail; Gutermuth, Jan

发表日期：2025

文献求助收藏

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study

在基于价值的常规护理中使用Tildrakizumab的患者自述健康状况：IV期阳性研究的52周中期数据

期刊:

影响因子:

doi:10.2147/PTT.S526748

Mrowietz, Ulrich; Sommer, Rachel; Gerdes, Sascha; Reguiai, Ziad; Weger, Wolfgang; Daudén, Esteban; Maul, Julia-Tatjana; Ghislain, Pierre-Dominique; Laws, Philip M; Naldi, Luigi; De Jong, Elke; Mburu, Sicily; Koscielny, Volker; Massana, Eric; Domenech, Arnau; Gaarn du Jardin, Kristian; Kasujee, Ismail; Augustin, Matthias

发表日期：2025

文献求助收藏

Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel

制定用于评估光化性角化病临床医生和患者报告结果的问卷：专家组的研究结果

期刊:

影响因子:

doi:10.1016/j.jdin.2023.09.006

Berman, Brian; Armstrong, April; Lebwohl, Mark; Grada, Ayman; Bhatia, Neal; Patel, Vishal A; Rigel, Darrell; Del Rosso, James; Schlesinger, Todd; Kircik, Leon; Salem, Raidah; Narayanan, Siva; Kasujee, Ismail

发表日期：2024

文献求助收藏

Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)

在真实世界环境中，使用tildrakizumab进行基于价值的护理的患者报告健康状况：一项多国、IV期、1队列前瞻性观察研究（POSITIVE研究）的方案

期刊:BMJ Open

影响因子:2.3

doi:10.1136/bmjopen-2021-060536

Augustin, Matthias; Sommer, Rachel; Daudén, Esteban; Laws, Philip; de Jong, Elke; Fabbrocini, Gabriella; Naldi, Luigi; Navarini, Alexander; Lambert, Jo; Reguiai, Ziad; Gerdes, Sascha; Massana, Eric; Obis, Teresa; Kasujee, Ismail; Mrowietz, Ulrich

发表日期：2023

文献求助收藏

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis

一项回顾性真实世界研究评估了Tildrakizumab在英国中重度慢性斑块状银屑病成年患者中的有效性和耐受性

期刊:Dermatology and Therapy

影响因子:4.2

doi:10.1007/s13555-022-00800-3

Becher, Gabrielle; Conner, Sophia; Ingram, Jennifer A; Stephen, Karen E; McInnes, Alison C; Heald, Adrian H; Riley, Paul A; Davies, Mark; Domenech, Arnau; Kasujee, Ismail

银屑病

发表日期：2022

文献求助收藏

Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies

银屑病患者非酒精性脂肪性肝病（NAFLD）：系统治疗对肝脏影响的综述

期刊:

影响因子:

doi:10.2147/PTT.S342911

Balak, Deepak M W; Piaserico, Stefano; Kasujee, Ismail

Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

IgE还是嗜酸性粒细胞才是过敏性哮喘发病机制中的关键因素？我们问的问题是否正确？

期刊:Respiratory Research

影响因子:5

doi:10.1186/s12931-018-0813-0

Matucci, Andrea; Vultaggio, Alessandra; Maggi, Enrico; Kasujee, Ismail

Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma

仍在为呼吸而战：一项关于重度哮喘的挑战和影响的患者调查

期刊:Erj Open Research

影响因子:4

doi:10.1183/23120541.00076-2018

Katsaounou, Paraskevi; Odemyr, Mikaela; Spranger, Otto; Hyland, Michael E; Kroegel, Claus; Conde, Lorena Garcia; Gore, Robin; Menzella, Francesco; Domingo Ribas, Christian; Morais-Almeida, Mario; Gasser, Matthias; Kasujee, Ismail

哮喘

发表日期：2018

文献求助收藏

Predictors of Flares and Disease Severity in Patients With Atopic Dermatitis Using Machine Learning

利用机器学习预测特应性皮炎患者的病情发作和严重程度

Systematic Review of the Use of the WHO-5 Well-Being Index Across Different Disease Areas

WHO-5健康指数在不同疾病领域应用情况的系统评价

European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol

一项欧洲多中心前瞻性观察性IV期临床研究，旨在评估lebrikizumab对中重度特应性皮炎患者健康相关福祉和皮肤表现控制的影响（ADTrust）：研究方案

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study

在基于价值的常规护理中使用Tildrakizumab的患者自述健康状况：IV期阳性研究的52周中期数据

Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel

制定用于评估光化性角化病临床医生和患者报告结果的问卷：专家组的研究结果

Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)

在真实世界环境中，使用tildrakizumab进行基于价值的护理的患者报告健康状况：一项多国、IV期、1队列前瞻性观察研究（POSITIVE研究）的方案

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis

一项回顾性真实世界研究评估了Tildrakizumab在英国中重度慢性斑块状银屑病成年患者中的有效性和耐受性

Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies

银屑病患者非酒精性脂肪性肝病（NAFLD）：系统治疗对肝脏影响的综述

Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

IgE还是嗜酸性粒细胞才是过敏性哮喘发病机制中的关键因素？我们问的问题是否正确？

Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma

仍在为呼吸而战：一项关于重度哮喘的挑战和影响的患者调查